Van ECK Associates Corp Cuts Holdings in Edwards Lifesciences Corporation $EW

Posted by Francis Steltz on Sep 1st, 2026

Van ECK Associates Corp lessened its stake in Edwards Lifesciences Corporation (NYSE:EW – Free Report) by 9.8% in the second quarter, Holdings Channel.com reports. The institutional investor owned 126,258 shares of the medical research company’s stock after selling 13,722 shares during the quarter. Van ECK Associates Corp’s holdings in Edwards Lifesciences were worth $11,421,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently made changes to their positions in EW. Hanson & Doremus Investment Management purchased a new position in Edwards Lifesciences in the first quarter worth $25,000. JPL Wealth Management LLC bought a new stake in Edwards Lifesciences during the third quarter worth about $25,000. MV Capital Management Inc. bought a new stake in Edwards Lifesciences during the fourth quarter worth about $26,000. RMG Wealth Management LLC purchased a new position in shares of Edwards Lifesciences in the 1st quarter worth about $26,000. Finally, Pin Oak Investment Advisors Inc. purchased a new position in shares of Edwards Lifesciences in the 2nd quarter worth about $26,000. Institutional investors own 79.46% of the company’s stock.

Edwards Lifesciences Stock Up 0.7%

EW opened at $90.86 on Tuesday. Edwards Lifesciences Corporation has a 12 month low of $72.30 and a 12 month high of $96.29. The company has a current ratio of 4.52, a quick ratio of 3.77 and a debt-to-equity ratio of 0.06. The business’s 50-day moving average price is $89.64 and its 200-day moving average price is $85.18. The company has a market cap of $52.32 billion, a P/E ratio of 52.22, a P/E/G ratio of 2.37 and a beta of 0.85.

Edwards Lifesciences (NYSE:EW – Get Free Report) last issued its earnings results on Thursday, July 23rd. The medical research company reported $0.78 earnings per share for the quarter, beating the consensus estimate of $0.74 by $0.04. Edwards Lifesciences had a return on equity of 15.68% and a net margin of 15.43%.The company had revenue of $1.74 billion during the quarter, compared to analysts’ expectations of $1.70 billion. During the same period in the prior year, the business posted $0.67 EPS. Edwards Lifesciences’s quarterly revenue was up 13.6% compared to the same quarter last year. Edwards Lifesciences has set its Q3 2026 guidance at 0.710-0.770 EPS and its FY 2026 guidance at 2.950-3.050 EPS. On average, equities analysts expect that Edwards Lifesciences Corporation will post 3 EPS for the current year.

Analyst Upgrades and Downgrades

A number of brokerages recently weighed in on EW. Leerink Partners raised Edwards Lifesciences from a “market perform” rating to an “outperform” rating and raised their price objective for the company from $87.00 to $101.00 in a report on Friday, July 24th. UBS Group assumed coverage on Edwards Lifesciences in a research note on Tuesday, July 28th. They issued a “buy” rating and a $110.00 target price for the company. Mizuho increased their price target on shares of Edwards Lifesciences from $100.00 to $105.00 and gave the company an “outperform” rating in a research report on Wednesday, July 15th. Royal Bank Of Canada lifted their price target on shares of Edwards Lifesciences from $100.00 to $110.00 and gave the stock an “outperform” rating in a research note on Monday, July 13th. Finally, Wall Street Zen lowered shares of Edwards Lifesciences from a “buy” rating to a “hold” rating in a report on Saturday, July 4th. Seventeen research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $100.27.

Get Our Latest Analysis on EW

Insider Buying and Selling at Edwards Lifesciences

In related news, SVP Andrew M. Dahl sold 544 shares of the company’s stock in a transaction on Monday, August 31st. The shares were sold at an average price of $91.06, for a total transaction of $49,536.64. Following the completion of the sale, the senior vice president directly owned 14,868 shares in the company, valued at $1,353,880.08. This represents a 3.53% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, VP Annette Bruls sold 2,644 shares of the stock in a transaction on Friday, August 28th. The shares were sold at an average price of $89.98, for a total transaction of $237,907.12. Following the sale, the vice president directly owned 17,984 shares of the company’s stock, valued at $1,618,200.32. The trade was a 12.82% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders sold 5,045 shares of company stock worth $457,749. 0.31% of the stock is currently owned by insiders.

Edwards Lifesciences Profile

(Free Report)

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.